EU Funded Projects
DiCE is involved in several EU-funded research projects. You can find separate sections dedicated to each of these projects, containing information on their duration, progress, aim, valuable updates about each, DiCE’s role in these, as well as a list of the partners involved, and contact information in case you would like to receive more details on the specific project you are interested in.
AI can help clinicians make sense of their own data by automating much of the treatment and analysis. The AIDA project aims to bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Read more.
The aim of the DISCERN project is to identify the causes of three poorly understood cancers in Europe – renal, pancreatic, and colorectal cancer – and to help explain the geographical distribution of these cancer types, including their high incidence in central and eastern Europe. The goal of DISCERN is to uncover novel causes for each of these three cancer types and to provide the critical evidence base required to develop new prevention strategies for these cancers in Europe. Read more.
The EU-funded ECOPOP project aims to assess the safety, efficacy, and quality of life outcomes of endoscopic tumour removal for early-stage colorectal cancer (CRC) compared with surgery. Through three international randomised trials, it will develop AI-guided criteria to identify high-risk lesions using biomarkers and advanced imaging. By promoting less invasive, organ-preserving, and cost-effective treatment options, ECOPOP seeks to improve patient care, reduce surgical burden—especially for elderly patients—and shape future clinical practice guidelines for early CRC management. Read more.
With the ENTERO project we aim to raise awareness amongst medical professionals, researchers, political authorities, patient associations, and the public about the global health challenges related to early-onset digestive cancers, their prevention, diagnosis, and treatment through the organisation of a high-level science-policy-society conference with a wide European Union dimension. Read more.
The EU-funded EU-CIP project will create the European Cancer Patient Digital Centre (ECPDC) Information Portal to improve access to reliable, evidence-based cancer information across Europe. It will provide resources on prevention, early detection, diagnosis, treatment, rehabilitation, and palliative care, focusing on high-incidence and paediatric cancers. A Common Library of Content will serve all Member States, supported by patient organisations. Through its modular design, EU-CIP will integrate with existing health systems, promoting the EU Cancer Mission and Europe’s Beating Cancer Plan. Read more.
The GUIDE.MRD project aims to address this challenge by exploring how blood tests could be used to identify which patients might benefit from additional treatment, and which patients would likely not benefit from treatment. The project focuses on patients with lung, pancreatic and colorectal cancers. Read more.
The HoloSurge project aims to refine the organ hologram technology, which was developed by Norwegian medtech company HoloCare. This technology will be used to power informed surgical decision-making. It provides liver surgeons with interactive 3D holograms of organs and can be used by doctors to tailor operations to each person’s individual anatomy. Read more.
READI (Research in Europe and Diversity Inclusion) aims to make clinical research fairer and more inclusive by improving access and participation for under-represented patients. It equips patients, researchers and organisations with tools, training and digital resources to design and run inclusive trials. By tackling barriers such as mistrust and limited awareness, READI ensures that treatments are tested across diverse populations, improving equity and outcomes for all patients. Read more.
The overarching objective of SAGITTARIUS is to use liquid biopsy (LB), a new innovative assay for detecting the circulating tumour DNA (ctDNA) in the blood, to personalise the post-surgical care of patients with loco-regional stage III and high-risk stage II colon cancer (LRCC). Read more.
The smartCARE project aims to co-create the Cancer Survivor Smartcard App with third-party app developers. The mobile application provides cancer survivors with easy access to their clinical history and treatment summary, which can be shared with relatives and professionals. Read more.
There is no effective screening method available in Europe for the prevention of gastric cancer. TOGAS aims to provide the missing evidence-based knowledge that can be used to design, plan and implement appropriate gastric cancer prevention across the EU. Read more.